Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I study

Clinical Pharmacology in Drug Development

Volumn 3, Issue 5, 2014, Pages 388-395

  Kretsos, Kosmas ^a   Golor, Georg ^b   Jullion, Astrid ^c   Hickling, Matthew ^a   McCabe, Suzanne ^a   Shaw, Stevan ^a   Jose, Joby ^a   Oliver, Ruth ^a  

^a UCB PHARMA   (Belgium)

^b PAREXEL INTERNATIONAL   (United States)

^c Arlenda   (Belgium)

Author keywords

Anti IL 6; First in human; Olokizumab; Pharmacokinetics; Safety

Indexed keywords

ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CREATINE KINASE; INTERLEUKIN 6; OLOKIZUMAB; PLACEBO; TRIACYLGLYCEROL; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; LEUKOCYTE COUNT; MALE; NEUTROPHIL COUNT; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; ADOLESCENT; BIOAVAILABILITY; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; DRUG MONITORING; GERMANY; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; MIDDLE AGED; PROCEDURES; STATISTICAL MODEL; SUBCUTANEOUS DRUG ADMINISTRATION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DOUBLE-BLIND METHOD; DRUG MONITORING; GERMANY; HALF-LIFE; HEALTHY VOLUNTEERS; HUMANS; INFUSIONS, INTRAVENOUS; INFUSIONS, SUBCUTANEOUS; LINEAR MODELS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; YOUNG ADULT;

EID: 84908539717     PISSN: 2160763X     EISSN: 21607648     Source Type: Journal    
DOI: 10.1002/cpdd.121     Document Type: Article

References (28)

1. Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res. 2002; 4(Suppl 3):S233-S242.
2. Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond). 2012; 122:143-159.
3. Yoshizaki K, Nishimoto N, Mihara M, Kishimoto T. Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Springer Semin Immunopathol. 1998; 20:247-259.
4. Park JY, Pillinger MH. Interleukin-6 in the pathogenesis of rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007; 65(Suppl 1):S4-S10.
5. Cottone M, Orlando A, Renna S. Investigational agents for Crohn's disease. Expert Opin Investig Drugs. 2010; 19:1147-1159.
6. Woodrick RS, Ruderman EM. Interleukin 6 inhibition-RA and beyond. Bull NYU Hosp Jt Dis. 2011; 69:225-229.
7. Dayer JM, Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford). 2010; 49:15-24.
8. Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006; 54:2817-2829.
9. Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, p lacebo-controlled trial. Arthritis Rheum. 2004; 50:1761-1769.
10. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008; 371:987-997.
11. Boulanger MJ, Chow DC, Brevnova EE, Garcia KC. Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science. 2003; 300:2101-2104.
12. Somers W, Stahl M, Seehra JS. 1.9 A crystal structure of interleukin 6: implications for a novel mode of receptor dimerization and signaling. EMBO J. 1997; 16:989-997.
13. Shaw S, Marshall D, Neale H, Kretsos K, Bourne T, Lawson A. Comparison of anti-interleukin-6 and anti-interleukin-6 receptor antibodies using in vivo functional systems. 1814 at: American College of Rheumatology 2011 Annual Scientific Meeting, Chicago, IL; 4 November-9 November, 2011.
14. Ramanujan S, Young D, Maisonpierre P, Shaw S, Chan J, Kretsos K. Mathematical modeling of interleukin-6 signaling inhibition: comparative efficiency of different intervention strategies. 43 (poster) at: American College of Rheumatology 2011 Annual Scientific Meeting, Chicago, IL; 4 November-9 November, 2011.
15. Duff GW. Expert Group on phase one clinical trials, final report. London: Department of Health; 2006, http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_063117 (accessed March 4, 2008).
16. European Medicines Agency. Guidelines on strategies to identify and mitigate risks for first-in-human clinical trials with investivational medicinal products. 2007. Available at: www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002988.pdf (accessed March 2013).
17. Food and Drug Administration. Guidance for Industry, estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. 2005. Available at: www.fda.gov/downloads/Drugs/./Guidances/UCM078932.pdf (accessed March 2013).
18. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. Department of Health and Human Services, National Institutes of Health. 2009. Available at: ftp://ftp1.nci.nih.gov/pub/cacore/EVS/CTCAE/Archive/CTCAE_4.02_2009-09-15_QuickReference:8.5x11.pdf (accessed March 2013).
19. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006; 54:1390-1400.
20. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004; 50:1400-1411.
21. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999; 354:1932-1939.
22. Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990; 12:1179-1186.
23. Zhang Z, Fuentes NL, Fuller GM. Characterization of the IL-6 responsive elements in the gamma fibrinogen gene promoter. J Biol Chem. 1995; 270:24287-24291.
24. Suwa T, Hogg JC, English D, Van Eeden SF. Interleukin-6 induces demargination of intravascular neutrophils and shortens their transit in marrow. Am J Physiol Heart Circ Physiol. 2000; 279:H2954-H2960.
25. Zhang X, Peck R. Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis. Expert Rev Clin Pharmacol. 2011; 4:539-558.
26. Xu Z, Bouman-Thio E, Comisar C, et al. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-inhuman study. Br J Clin Pharmacol. 2011; 72:270-281.
27. Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006; 11:81-88.
28. Robak T, Gladalska A, Stepien H, Robak T. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Med Inflam. 1998; 7:347-353.